ArticlePediatric research2026
Brain-derived neurotrophic factor (BDNF) in neonatal blood: associations with respiratory disease in extremely preterm infants.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurotrophins, including brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4), have been associated with the development of bronchopulmonary dysplasia (BPD) in preterm infants.
objectivesTo evaluate relationships between early postnatal BDNF and NT-4 levels and adverse pulmonary outcomes among preterm infants.
methodsWe analyzed data from the Extremely Low Gestational Age Newborn (ELGAN) cohort. Serum BDNF and NT-4 were measured at birth and postnatal days 7, 14, 21, and 28. Pulmonary outcomes included BPD and early respiratory patterns predictive of BPD, specifically, pulmonary deterioration (PD) and early and persistent pulmonary dysfunction (EPPD). Associations were evaluated using regression models adjusted for perinatal confounders.
resultsNT-4 levels were not associated with BPD risk. Persistently high BDNF trajectories were associated with reduced risk, while persistently low BDNF was associated with increased risk of BPD, PD, and EPPD (BPD: OR 2.75; 95% CI 1.83-4.15; PD: OR 3.13; 95% CI 1.60-6.14; and EPPD: OR 7.94; 95% CI 3.70-17.04). Infants with persistently low and intermediate BDNF trajectories had higher risk of adverse pulmonary outcomes compared with those with persistently high BDNF levels.
conclusionsLongitudinal BDNF trajectories identify subgroups of preterm infants at differential risk for adverse respiratory outcomes. Persistently high BDNF during the first month of life may be protective and a potential target for preventive strategies. IMPACT: Persistently low brain-derived neurotrophic factor (BDNF) levels during the first postnatal month are associated with increased risk and severity of bronchopulmonary dysplasia (BPD) and early adverse respiratory phenotypes in extremely preterm infants. Longitudinal BDNF trajectories provide greater discrimination of respiratory risk than single time-point measurements. Infants with persistently high BDNF have the lowest risk of pulmonary deterioration, early persistent pulmonary dysfunction, and severe BPD. These findings support BDNF as a potential early biomarker of lung disease progression in preterm infants.
Identifiers
42567895What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.